tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Body Weight D001835 333 associated lipids
Lung Neoplasms D008175 171 associated lipids
Adenocarcinoma D000230 166 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Edema D004487 152 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hemolysis D006461 131 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Inflammation D007249 119 associated lipids
Hypertension D006973 115 associated lipids
Glioma D005910 112 associated lipids
Weight Gain D015430 101 associated lipids
Insulin Resistance D007333 99 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Brain Ischemia D002545 89 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Seizures D012640 87 associated lipids
Arteriosclerosis D001161 86 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Atherosclerosis D050197 85 associated lipids
Alzheimer Disease D000544 76 associated lipids
Stomach Ulcer D013276 75 associated lipids
Leukemia D007938 74 associated lipids
Hyperlipidemias D006949 73 associated lipids
Colitis D003092 69 associated lipids
Melanoma D008545 69 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Reperfusion Injury D015427 65 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Pain D010146 64 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Weight Loss D015431 56 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Parkinson Disease D010300 53 associated lipids
Nerve Degeneration D009410 53 associated lipids
Leukemia, Myeloid D007951 52 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Osteosarcoma D012516 50 associated lipids
Thrombosis D013927 49 associated lipids
Precancerous Conditions D011230 48 associated lipids
Fatty Liver D005234 48 associated lipids
Psoriasis D011565 47 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Leukemia P388 D007941 43 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Hyperalgesia D006930 42 associated lipids
Hypotension D007022 41 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Arthritis D001168 41 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Lung Diseases D008171 37 associated lipids
Nervous System Diseases D009422 37 associated lipids
Heart Failure D006333 36 associated lipids
Glomerulonephritis D005921 35 associated lipids
Acne Vulgaris D000152 35 associated lipids
Infarction, Middle Cerebral Artery D020244 35 associated lipids
Fever D005334 35 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Burns D002056 34 associated lipids
Cataract D002386 34 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Memory Disorders D008569 33 associated lipids
Peripheral Nervous System Diseases D010523 33 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Uremia D014511 33 associated lipids
Stroke D020521 32 associated lipids
Diarrhea D003967 32 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Liver Diseases D008107 31 associated lipids
Cardiomegaly D006332 31 associated lipids
Catalepsy D002375 30 associated lipids
Dermatitis D003872 30 associated lipids
Drug Eruptions D003875 30 associated lipids
Proteinuria D011507 30 associated lipids
Obesity D009765 29 associated lipids
Kidney Diseases D007674 29 associated lipids
Ventricular Remodeling D020257 28 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Brain Diseases D001927 27 associated lipids
Endotoxemia D019446 27 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Ascites D001201 25 associated lipids
Leukemia-Lymphoma, Adult T-Cell D015459 25 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Lymphoma, B-Cell D016393 24 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Fibrosis D005355 23 associated lipids
Cystitis D003556 23 associated lipids
Leukemia, T-Cell D015458 23 associated lipids
Cholestasis D002779 23 associated lipids
Neoplasm Invasiveness D009361 23 associated lipids
Erythema D004890 22 associated lipids
Hypoxia-Ischemia, Brain D020925 22 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Morris RE In vivo immunopharmacology of the macrolides FK 506 and rapamycin: toward the era of rational immunosuppressive drug discovery, development, and use. 1991 Transplant. Proc. pmid:1721257
Kobayashi M et al. FK 506 assay past and present--characteristics of FK 506 ELISA. 1991 Transplant. Proc. pmid:1721258
Warty VS et al. Practical aspects of FK 506 analysis (Pittsburgh experience). 1991 Transplant. Proc. pmid:1721259
Jusko WJ and D'Ambrosio R Monitoring FK 506 concentrations in plasma and whole blood. 1991 Transplant. Proc. pmid:1721260
Venkataramanan R et al. Pharmacokinetics of FK 506 in transplant patients. 1991 Transplant. Proc. pmid:1721261
Loréal O et al. FK 506 is less cytotoxic than cyclosporine to human and rat hepatocytes in vitro. 1991 Transplant. Proc. pmid:1721289
McCauley J et al. Cyclosporine and FK 506 induced inhibition of renal epithelial cell proliferation. 1991 Transplant. Proc. pmid:1721290
McLachlan G et al. Growth inhibition of the MOLT-4 human T-leukemia cell line. A comparison of cyclosporine and FK 506. 1991 Transplant. Proc. pmid:1721291
Akselband Y et al. Rapamycin inhibits spontaneous and fibroblast growth factor beta-stimulated proliferation of endothelial cells and fibroblasts. 1991 Transplant. Proc. pmid:1721292
Fukuzawa M et al. Effect of FK 506 on CD4+ and CD8+ T-cell function in vivo. 1991 Transplant. Proc. pmid:1721321
Takaori K et al. Effects of FK 506 on in vivo immunity in comparison to cyclosporine. 1991 Transplant. Proc. pmid:1721322
Jordan ML et al. Inhibition of T-cell function by FK 506 and cyclosporine is not accompanied by alterations in intracellular calcium. 1991 Transplant. Proc. pmid:1721323
Motta I et al. FK 506 favors the generation of memory T cells in vitro. 1991 Transplant. Proc. pmid:1721324
Paul AA et al. CMV retinitis and the use of FK 506. 1991 Transplant. Proc. pmid:1721354
Keicho N et al. Effects of an immunosuppressant, FK506, on interleukin 1 alpha production by human macrophages and a macrophage-like cell line, U937. 1991 Cell. Immunol. pmid:1703047
Reyes J et al. Posttransplant lymphoproliferative disorders occurring under primary FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721355
White DJ FK506: the promise and the paradox. 1991 Clin. Exp. Immunol. pmid:1703053
Whiteside TL et al. Serial monitoring of immunologic function and phenotype of lymphocytes in the blood of transplanted patients randomized to cyclosporine or FK 506. 1991 Transplant. Proc. pmid:1721356
Frayha HH et al. Lymphoproliferative disorder in a liver transplant patient on FK 506. 1991 Lancet pmid:1703258
Burman K and Crawford DH Effect of FK 506 on Epstein-Barr virus specific cytotoxic T cells. 1991 Lancet pmid:1703259
Tauxe WN et al. A comparison of the renal effects (ERPF, GFR, and FF) of FK 506 and cyclosporine in patients with liver transplantation. 1991 Transplant. Proc. pmid:1721386
McCauley J et al. Renal function after conversion from cyclosporine to FK 506 in liver transplant patients. 1991 Transplant. Proc. pmid:1721387
Hossein-Nia M et al. Urinary proteins as a marker of drug-induced renal damage following treatment with cyclosporine or FK 506. 1991 Transplant. Proc. pmid:1721388
Winkler M et al. Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients. 1991 Transplant. Proc. pmid:1721389
Tzakis AG et al. FK 506 rescue in chronic graft-versus-host-disease after bone marrow transplantation. 1991 Transplant. Proc. pmid:1721416
Masaoka T et al. Phase II study of FK 506 for allogeneic bone marrow transplantation. 1991 Transplant. Proc. pmid:1721417
Markus PM et al. The effect of cyclosporine, rapamycin and FK 506 the survival following allogeneic bone marrow transplantation. 1991 Transplant. Proc. pmid:1721418
Cooper MH et al. The induction of pseudo-graft-versus-host disease following syngeneic bone marrow transplantation using FK 506. 1991 Transplant. Proc. pmid:1721419
Brabletz T et al. The immunosuppressives FK 506 and cyclosporin A inhibit the generation of protein factors binding to the two purine boxes of the interleukin 2 enhancer. 1991 Nucleic Acids Res. pmid:1707162
Iwaki Y et al. Replacement of donor lymphoid tissue in small-bowel transplants. 1991 Lancet pmid:1707470
Markus PM et al. Effects of in vivo treatment with FK506 on natural killer cells in rats. 1991 Transplantation pmid:1707562
Abu-Elmagd K et al. FK 506: a new therapeutic agent for severe recalcitrant psoriasis. 1991 Transplant. Proc. pmid:1721449
Nikolaidis NL et al. Metabolic effects of FK 506 in patients with severe psoriasis: short-term follow-up of seven cases. 1991 Transplant. Proc. pmid:1721450
Abu-Elmagd K et al. Efficacy of FK 506 in the treatment of recalcitrant pyoderma gangrenosum. 1991 Transplant. Proc. pmid:1721451
Banerji SS et al. The immunosuppressant FK-506 specifically inhibits mitogen-induced activation of the interleukin-2 promoter and the isolated enhancer elements NFIL-2A and NF-AT1. 1991 Mol. Cell. Biol. pmid:1712901
Markus PM et al. FK 506 reverses acute graft-versus-host disease after allogeneic bone marrow transplantation in rats. 1991 Surgery pmid:1713358
Farley DE et al. The effect of two new immunosuppressive agents, FK506 and didemnin B, in murine pregnancy. 1991 Transplantation pmid:1713360
Vathsala A et al. The immunosuppressive antagonism of low doses of FK506 and cyclosporine. 1991 Transplantation pmid:1713361
Kawano K et al. A protective effect of FK506 in ischemically injured rat livers. 1991 Transplantation pmid:1713362
Katz IA et al. Comparison of the effects of FK506 and cyclosporine on bone mineral metabolism in the rat. A pilot study. 1991 Transplantation pmid:1716801
Jiang H et al. Effect of FK-506 on heart allograft survival in the highly sensitized recipient rats as compared with ciclosporin and 15-deoxyspergualin. 1991 Eur Surg Res pmid:1723683
Pezze JL and Whiteman K Transplantation's newest weapon FK 506. 1991 Am J Nurs pmid:1716857
Fung JJ et al. Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. 1991 Transplant. Proc. pmid:1703682
Marquis-Omer D et al. Stabilization of the FK506 binding protein by ligand binding. 1991 Biochem. Biophys. Res. Commun. pmid:1716886
Wu J et al. Comparative immunoregulatory effects of rapamycin, FK 506 and cyclosporine on mitogen-induced cytokine production and lymphoproliferation. 1991 Transplant. Proc. pmid:1703683
Sakai K et al. [The effect of a new immunosuppressive agent, FK-506, on xenogeneic neural transplantation in rodents--comparison with cyclosporin A]. 1991 No To Shinkei pmid:1716937
Romanowski P et al. [Synthetic immunomodulators designed on the basis of natural products of microorganisms]. 1991 Postepy Biochem. pmid:1725924
Altmeyer A et al. Unexpected up-regulation of gene expression by cyclosporin A and FK-506 in a T-cell lymphoma: both immunosuppressants augment Ly-6E antigen induction by interferon-gamma in the presence of ionomycin. 1991 Int. J. Immunopharmacol. pmid:1726093
Gordon RD et al. Liver transplantation at the University of Pittsburgh, 1984 to 1990. 1991 Clin Transpl pmid:1726458
Jamieson NV et al. Orthotopic liver transplantation at Addenbrooke's Hospital Cambridge 1968 to 1991. 1991 Clin Transpl pmid:1726459